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Abstract 
Papillary thyroid carcinoma (PTC) has an excellent prognosis with a relatively low mortality rate, but a small portion of PTC patients suffer 
from an aggressive form of the disease. In such cases early detection of lymph node metastasis (LNM) is as paramount as it is problematic. 
The routine use of central neck lymph node dissection is not recommended. New methods to detect LNM are needed. MicroRNAs are 
a potential biomarker for diagnosis and prognosis of PTC. In this review we summarise the current knowledge regarding dysregulated 
miRNAs and their association with LNM in PTS patients.
The PubMed and EBSCO databases were searched using terms for “microRNA”, “thyroid carcinoma”, and “prognosis” by using Boolean 
operators. Based on eligibility and exclusion criteria, articles were screened and reviewed in full, methodological data of included studies 
were extracted, and risk of bias analysis performed. 
In total, 446 unique studies were extracted from the mentioned databases, and based on inclusion and exclusion criteria 27 studies were 
included in this review. Of them 17 analysed tissue microRNAs, 5 analysed circulating microRNAs, and 5 studies analysed both tissue and 
circulating samples. MiRNA-146B, miRNA-221, miRNA-222, miRNA-21, miRNA-204, miRNA-451, miRNA-199a-3p, and miRNA-30a-3p 
were dysregulated in at least 2 separate studies. A sizable portion of studies failed to show statistically significant differences in miRNA 
expression between LNM-positive and -negative patients. Different methodologies and disparities of patient populations could explain 
these discrepancies.
This research supports the statement that specific up- and downregulated miRNAs are associated with LNM in PTC patients. However, 
the prognostic value of these miRNAs is limited. Additional targeted cohort studies are required to elucidate the role of miRNAs in defin-
ing individualised treatment strategies for thyroid cancer patients. (Endokrynol Pol 2021; 72 (2): 145–152)
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Introduction 
Thyroid cancer is the most frequently occurring endo-
crine malignancy, with an increasing rate of incidence 
over the last 3 decades [1]. It accounts for 1.7% of all 
malignant tumours worldwide [2]. Papillary thyroid 
carcinoma (PTC) accounts for up to 85% of all thyroid 
cancers [3]. Generally, PTC has an excellent prognosis 
with a relatively low mortality rate, but a small portion 
of PTC patients suffer from an aggressive form of the 
disease, with tumour invasion and metastasis [4]. The 
detection of neck lymph node metastasis (LNM) — es-
pecially subclinical — of thyroid cancer using imaging 
methods (ultrasound, computer tomography, magnetic 
resonance imaging) is often problematic [5]. In up to 
60% of imaging lymph node-negative patients, cervical 
LNM are found on histology [6]. This could result in 
incomplete clinical treatment. The American Thyroid 
Association Management guidelines recommend the 
use of central neck dissection for patients with clinically 
involved central nodes, but the use of prophylactic 
central node dissection (pCND) in patients without 
clinically detected central neck lymph nodes remains 
controversial [7]. Prophylactic central node dissection 
significantly reduces locoregional recurrence in PTC 
patients with clinically uninvolved central neck lymph 
nodes, but pCND is often associated with postoperative 
complications. Patients with pCND have significantly 
higher chances of transient recurrent laryngeal nerve 
injury and transient or permanent hypocalcaemia [8]. 
Therefore, accurate identification of LNM is of crucial 
importance in optimising individualised PTC treatment. 
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Reviews. The Study was written in accordance with the 
guidelines proposed by the preferred reporting items 
for systematic review and meta-analyses (PRISMA) [13]. 
Search was performed by querying the PubMed and 
EBSCO databases with terms for “micro RNA”, “thyroid 
carcinoma”, and “prognosis” by using Boolean opera-
tors, for articles published prior to 2020-08-13 (Tab. 1). 
Two reviewers (R.L., V.J.) working independently us-
ing standardised forms screened titles and abstracts to 
identify potentially relevant studies. Articles of interest 
were further evaluated in their entirety (Fig. 1).
Studies were considered to be eligible if they: fo-
cused on patients with any type of papillary thyroid 
carcinoma or had information about clinicopathological 
patient characteristics. The effect of the dysregulated 
miRNA on cervical lymph node metastases was as-
sessed. Exclusion criteria consisted of the following: 
non-PTC thyroid cancer studies, non-English articles, 
reviews, letters, comments, and studies using miRNAs 
only for differentiation between benign and malignant 
thyroid lesions or studies with a primary focus on bio-
molecular mechanisms of miRNAs.
It is of note, reviewers elected not to exclude studies 
if they satisfied inclusion criteria but failed to find sta-
tistically significant differences in microRNA expression 
among LNM positive and negative groups.
Risk of bias was assessed using a quality assess-
ment tool for diagnostic accuracy studies (QUADAS-2). 
QUADAS-2 focuses on the quality of primary diagnos-
tic accuracy studies, but not on the patient cohorts, 
control groups, or blinding procedures. It consists of 
4 key domains covering patient selection, index test 
(in our case miRNA), reference standard, and flow of 
patients through the study as well as the timing of the 
index test and reference standard (“flow and timing”). 
These domains are assessed in terms of risk of bias 
Many researchers are looking for new testing meth-
ods to identify LNM before surgery. Advanced new mo-
lecular genetic biomarkers could identify patients with 
aggressive PTC for more aggressive treatment options.
MicroRNAs (miRNAs) are a class of non-coding 
RNAs approximately 19–24 nucleotides in length that 
can function as oncogenes or tumour suppressors by 
inhibiting the translation of tumour suppressor genes or 
by blocking the translation of oncogenes [9]. MicroRNAs 
modify gene expression by binding to specific targets 
in the 3’ untranslated region, and they are implicated 
in tumourigenesis of a variety of tissues [10]. Regula-
tion of classical oncogenes and tumour suppressor 
genes by miRNAs was easily identified as a hallmark of 
cancer research, transforming this class of small RNAs 
into potential targets for cancer diagnosis, prognosis, 
and therapy. With the availability of high-throughput, 
next-generation sequencing, miRNAs can be detected 
more accurately from controls compared with other 
miRNA microarrays, northern blots, and TaqMan mi-
croRNA Assays Human panel [11]. There has been a lot 
of interest in the feasibility of miRNAs as biomarkers for 
the diagnosis of thyroid cancer in recent years. Several 
miRNAs possibly associated with LNM were identified 
in patients with PTC [12].
In this review, we focus on miRNA expression in 
thyroid cancer to evaluate miRNA signatures associated 
with LNM. The objective of this systematic review is 
to summarise the current knowledge regarding dys-
regulated miRNAs and their association with LNM in 
patients with PTC.
Systematic literature analysis 
Systematic literature analysis was performed following 
the Cochrane Handbook for Interventional Systematic 
Table 1. Detailed search retrieval from PubMed and EBSCO databases, including results for terms and their combinations
No. Search details in PubMed Search details in EBSCO PubMed EBSCO
1
“thyroid cancer” [Title/Abstract] OR “thyroid carcinoma” 
[Title/Abstract] OR “thyroid nodule” [Title/Abstract]  
OR thyroid neoplasms [MeSH Terms]
(TI thyroid cancer OR AB thyroid cancer) 
OR (TI thyroid carcinoma  
OR AB thyroid carcinoma)  
OR (TI thyroid nodule  
OR AB thyroid nodule)
63,540 76,736
2
“micro RNA” [Title/Abstract] OR “miRNA”  
[Title/Abstract] OR „miR” [Title/Abstract]  
OR micrornas [MeSH Terms]
(TI micro RNA OR AB micro RNA)  
OR (TI miRNA OR AB miRNA)  
OR (TI miR OR AB miR)
114,487 134,624
3
“prognosis” [Title/Abstract] OR “prognos*  
”[Title/Abstract] OR “lymph node” [Title/Abstract]  
OR “metasta*” [Title/Abstract]  
OR prognosis [MeSH Terms]
(TI prognos* OR AB prognos*)  
OR (TI lymph node OR AB lymph node) 
OR (TI metasta* OR AB metasta*)
2,330,377 1,670,450
4 1 AND 2 1 AND 2 918 890
5 3 AND 4 3 AND 4 410 359
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and the first 3 are also assessed in terms of concerns 
regarding applicability. To help reach a judgement on 
the risk of bias, signalling questions were included [14]. 
QUADAS-2 review questions and specific guidance for 
this review were discussed among the reviewers, and 
then evaluation was performed by 2 reviewers work-
ing separately. 
Methodological and outcome data were extracted 
from the selected studies. Discrepancies between 2 re-
viewers in study selection (title and abstract screening, 
full article evaluation), data extraction, and risk of bias 
evaluation processes were discussed and a joint resolu-
tion was made.
Analysis results
The PubMed search yielded 410 possible studies and 
EMBSCO yielded 359. In total 446 unique studies were 
included in the further analysis after removing dupli-
cates. Based on the inclusion and exclusion criteria, 367 
studies were excluded after title and abstract screening 
(most were reviews and studies not addressing PTC or 
lacking clinicopathological data), and when the deci-
sion was not clear, the studies were analysed in full. Of 
the 79 full text publications, 27 studies were included 
in this review (Fig. 1). The 2 reviewers were in agree-
ment regarding study eligibility. The earliest study 
was published in May 2010 [15] and the latest in June 
2020 [16]. The included studies were from 7 countries: 
China (n = 20), Serbia (n = 2), Lithuania (n = 1), South 
Korea (n = 1), Taiwan (n = 1), Turkey (n = 1), and the 
USA (n = 1).
Study design
A methodological summary of the included studies is 
summarised in Supplementary File — Table S1.
From 27 studies, 17 analysed tissue microRNAs, 5 
analysed circulating microRNAs, and 5 studies analysed 
both tissue and circulating samples. Among studies ana-
lysing tissue, 11 evaluated freshly frozen (snap-frozen) 
samples, 9 analysed miRNAs from formalin-fixed 
paraffin-embedded tissue (FFPE), one analysed tissue 
from fine needle aspiration (FNA), and in 1 case the 
method of specimen preparation/extraction was not 
specified. In studies analysing circulating microRNAs, 
3 analysed plasmas, 4 — serum, 1 — blood (otherwise 
not specified), 1 — plasma exosomes, and 1 — both 
plasma and serum exosomes (Fig. 2).
For initial genome screening, 4 studies [15, 20–22] 
performed microarray, and 1 study [17] used Solexa 
sequencing, followed by qRT-PCR to validate re-
sults. However, of all the rest of the studies 21 per-
formed qRT-PCR [16, 19, 23–41] and 1 study performed 
northern blotting [18] to quantify miRNA expression for 
a priori selected miRNAs from the literature.
The studies employed a variety of statistical meth-
ods. Twenty-one studies compared continuous miRNA 
expression between different LNM groups. When para-
metric test assumptions were met, Student’s t-test and 
ANOVA were used, and when such assumptions were 
not met, Kruskal-Wallis H and Mann-Whitney U tests 
were used. Analysing associations between miRNA and 
LNM, one study [17] used Pearson’s correlation coeffi-
cient to correlate miRNAs from blood and tissue, and 2 
studies [26, 33] used multivariate logistic regression to as-
sess independent predictors for LNM. Six studies divided 
miRNA expression into low/high groups based on mean 
or median values, and then compared those groups as 
categorical variables using the chi-square test to assess 
differences between miRNA expression and LNM status 
[16, 28–31, 37]. Four studies [32, 38, 39, 41] performed 
ROC analysis to evaluate the diagnostic utility of miRNA 
769 articles identied
446 titles and abstracts screened
367 excluded (review, not
PTC, not English)
62 excluded (in vitro,
LNM not analysed)
323 duplicates
79 full text publications
27 included
Figure 1. Flowchart of study selection. PTC — papillary thyroid carcinoma; LNM — lymph node metastasis
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miRNA from post-surgical specimens may not neces-
sarily translate to changes measurable preoperatively 
(e.g. serum, FNA specimens). Additionally, all but one 
of the included studies performed clinically indicated 
or not specified cervical lymph node dissection, as op-
posed to prophylactic cervical lymph node dissection, 
and this could lead to a selection bias, favouring more 
advanced disease and missing early stages of cervical 
LNM. This could also explain why in a sizable portion 
of included studies there were more PTC patients with 
LNM than without LNM. 
Of note, only one [26] of the included studies 
specified PTC subtype in a LNM vs. no LNM context, 
providing separate analysis for all variants combined 
and classical variant in particular excluding Tall cell and 
follicular PTCs. 
in predicting LNM. One study [38] used univariate and 
multivariate Cox proportional hazard model to analyse 
miRNA as independent risk factors for LNM. 
A summary of the risk of bias analysis can be found 
in Supplementary File — Table S2, and Figure 3.
Most of the studies included in the analysis were at 
low risk of bias in all evaluated domains. However, in 
some studies the patient population and methodologi-
cal descriptions were not fully clear. Several previous 
studies showed discrepancies between miRNA pro-
files in surgically resected tissues and FNA material, 
which led other authors to conclude that the results 
from surgically resected material cannot be extrapo-
lated into preoperative use without further validation 
[42]. Therefore, this review attempted to find miRNA 





















0%            20%           40%           60%           80%          100% 0%            20%           40%           60%           80%          100%
Risk of bias
Applicability concers
Low             High             Unclear
Figure 3. Summary of risk of bias analysis by quality assessment tool for diagnostic accuracy studies (QUADAS-2)
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MicroRNA expression and LNM
Dysregulated miRNAs associated with LNM in the 
included studies are listed in Supplementary Table S3 
(with pre-operative specimens in bold). When the same 
miRNA was mentioned in at least 2 separate studies, 
they were listed in Table 2 (specimens obtained preop-
eratively are shown in bold).
miRNA-146B, miRNA-221, miRNA-222, miRNA-21, 
miRNA-204, miRNA-451, miRNA-199a-3p, and miR-
NA-30a-3p were mentioned in at least 2 separate stud-
ies. Similar at least two different studies excluding tissue 
specimen miRNA-221, miRNA-222, miRNA-146b, and 
miRNA-204 were found as well. Some studies analyzed 
not only differences between LNM-positive and -nega-
tive groups, but also tried to find differences in miRNA 
expression between groups based on LNM location in 
the neck lateral LNM vs. central LNM [21, 23, 36].
Most of the studies agreed on the presents of miRNA 
dysregulation; however, in some studies statistically 
significant differences were not identified (Tab. 2). 
In one study upregulated miRNA-451 was detected 
in patients with LNM [21] and downregulated by an-
other one [32].  
The same trend remains even in studies where 
specimens were available preoperatively. This could be 
explained by different methodologies, groups sizes, and 
disparities in patient populations, because all but one of 
the studies lymphadenectomies were performed only 
by clinical suspicion or the indication was not specified.
miRNA biomarkers predicting LNM in PTC 
Differentiated thyroid cells express a pool of miRNAs, 
alterations in the expression of which could induce 
neoplastic changes. A downregulation of miRNAs that 
ensure normal function of cells, or alternatively an up-
regulation of miRNAs that promote oncogenic effects, 
can lead to increased expression of oncogenes. That can 
result in the induction of the malignant effects of cell 
proliferation, differentiation, and apoptosis, leading to 
tumour growth and progression [43]. In this systematic 
review, we focused on exploring the utility of miRNA 
biomarkers predicting LNM in PTC.
MicroRNA-146
MicroRNA-146 is one of the most investigated miRNAs 
in thyroid cancer and has been shown to be reliably 
upregulated in PTC [24, 26, 34, 38, 40]. 
Functional analyses of miRNA-146 revealed its 
involvement in various cellular functions includ-
ing proliferation, migration, and invasion [44, 45]. 
Chou et al. demonstrated that miRNA-146b expression 
was an independent risk factor for poor prognosis in 
PTC [46]. 
Chen et al. indicated that microRNAs can be identi-
fied not only in tissue samples but also in serum and 
plasma in a remarkably stable form. That makes miRNA 
expression detection possible in blood samples and 
serum, serving as potential biomarkers to detect vari-
ous cancers. [47]. The clinical utility of using miRNAs 
as a biomarker in serum could be a diagnostic tool for 
identifying patients with LNM in PTC for more aggres-
sive treatment options.
Eleven articles in our review described the associa-
tion between miRNA-146 overexpression and LNM in 
PTC. Eight of these studies analysed tissue miRNA (4 
FFPE, 3 FF, and 1 FNA) [15, 19, 20, 22, 24, 26, 34, 40], 
2 — circulating samples (plasma exosome) [23, 38] 
and 1 — both tissue and circulating samples (FF and 
blood) [25].
Several independent groups of investigators ex-
amining microRNA in histological samples found the 
expression level of miRNA146b to be significantly el-
evated in patients with lymph node metastases [24, 26, 
40]. However, no significant correlation was observed 
in other studies [15, 19, 20, 22].
Sun et al. found positive associations between 
levels of miRNA-146a expression in PTC tissues and 
Table 2. Dysregulated miRNA mentioned in at least 2 separate studies
MiR Studies with ≠MiR Studies with ØMiR No statistically significant difference
146b [24, 26, 34, 38, 40] [15, 19, 20, 22, 23, 25]
221 [18, 19, 24, 26, 38, 40] [15, 18, 20, 23, 26]
222 [17, 19, 24, 26, 36, 38, 40] [15, 20, 23, 36]
21 [38, 40] [19. 26]
204 [38] [26, 39]
451 [21] [32]
199a-3p [31] [38]
30a-3p [22, 35, 38]
bold — specimens could be obtained preoperatively
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positive cervical lymph node metastasis. Nevertheless, 
the same study did not note significant differences in 
expression of miRNA-146b in the peripheral blood or 
in tissue between patients with PTC and LNM and pa-
tients with PTC but without LNM, which indicates that 
miRNA-146a and miRNA-146b expression in peripheral 
blood are not useful markers for LNM in PTC [25]. 
Yang et al. examined miRNA-146b expression in 
FNA, and malignancy was confirmed by histology, as 
a gold standard for accuracy. That study showed that 
levels of miR146b were significantly higher in PTCs 
with lymph node metastasis [34]. 
Jiang et al. explored the selected exosomal miR-
NAs as potential biomarkers predicting LNM in 
PTCs. Exosomal miRNA-146b-5p and miRNA-222-3p 
ROC analysis showed AUCs of 0.811 and 0.834, re-
spectively. Combining exosomal miRNA-146b-5p and 
miRNA-222-3p significantly improved the diagnostic 
value and increased the AUC to 0.895, with a sensitivity 
and specificity of 85.1% and 80.0%, respectively [38]. 
The only study in our review by Han et al. examined 
miRNA expression in the patients undergoing pro-
phylactic lymph node dissection. The specimens they 
used were FFPE. On FFPE specimens miRNA-146b-3p, 
miRNA-146b-5p, and miRNA-222 were identified as 
potential markers of LNM [26].
miRNA-221/222
Many PTC studies in our review identified expression 
of miRNA-221/222 as the most consistently upregulated 
miRNAs, with significant association with clinicopatho-
logical features. PTC with LNM showed higher tissue 
miRNA-221/222 expression in comparison to PTC 
without LNM [18, 19, 24, 26, 36, 40]. Jiang et al. revealed 
that a high serum miRNA-222 and miRNA-221 level has 
significant correlation with the presence of LNM [38]. 
Enhanced expression of serum miRNA-222 was also 
found in patients with cervical lymph node metastasis 
in a study by Yu et al. [17]. In an another study, Lee et 
al. [23] recruited PTC patients with and without LNM. 
Mean fold changes in plasma-derived miRNA-221 
(–4.86 ± 0.051), and miRNA-222 (–5.36 ± 0.91) in pa-
tients with LNM group were slightly higher than that 
of miR-221 (–5.06 ± 0.074), and miR-222 (–5.45 ± 0.079) 
in patients without LNM. However, without statistical 
significance.
miRNA-451
Another important member of the microRNA family is 
miRNA-451, which has been shown to be downregulat-
ed in various human tumours [48]. It is dysregulated in 
multiple cancers and take part in various human physi-
ological and pathological processes and cancer-related 
biological processes such as apoptosis, angiogenesis, 
proliferation, and metastasis [49–51]. It often acts as 
a tumour suppressor gene in various cancers. However, 
little is known about its role in PTC.
In the reviewed articles we found that the data 
about miRNA-451 association with LNM in PTC are 
controversial. The results of a study by Zhang et al. 
[32] indicated a strong correlation with lower miR-451 
levels in PTC patients with LNM, suggesting that the 
tissue miRNA-451 level is also a “good” biomarker 
(AUC = 0.792) for lymph node metastasis. Expression 
of serum miR-451 in positive LNM patients’ samples 
was only modestly (77%) lower than in LNM-negative 
patients. ROC analysis of serum miRNA-451 as a bio-
marker for evaluation of lymph node status was per-
formed. A value of 0.690 in AUC would indicate that 
it is a possible “modest” biomarker for lymph node 
metastasis. 
Conversely, the findings of Wang et al. [21] revealed 
that the expression of miRNA-451 tissue was signifi-
cantly upregulated in PTC with LNM, compared to 
PTC cases without LNM. These findings suggest an on-
cogenic role for miRNA-451 in PTC. Further studies 
in larger cohorts are needed to explain the discrepant 
results on the role of miRNA-451 in thyroid cancer. 
MicroRNA-199a-3p
MicroRNA-199a-3p is downregulated in a number of 
different cancers, such as ovarian carcinoma, colorec-
tal cancers, and hepatocellular carcinoma [52-54]. The 
results of a study by Liu et al. [31] showed positive 
associations between levels of miRNA-199a-3p expres-
sion in PTC tissues and positive cervical lymph node 
metastasis.
The same study revealed that low miR-199a-3p 
expression was associated with LNM (p = 0.036) and 
recurrence of LNM (p = 0.03). These results suggest 
that the detection of miRNA-199a-3p in the PTC could 
reflect metastasis and predict prognosis. 
Jiang et al. [38] recruited 136 patients with PTC. The 
expression level of serum miRNA-199a-3p was exam-
ined in patients with and without LNM. However, the 
difference between groups was not significant. 
One of the factors limiting the comparison of miRNA 
changes between different publications is that most 
studies use their own rather subjective miRNA expres-
sion values, and no absolute levels of target miRNAs 
are set, which complicates the external validity usage 
of miRNA as a clinical tool. 
In addition, as was noted in another review [55], 
analysis of miRNA expression and underlying mecha-
nisms cannot be related to a single miRNA analysis. Due 
to non-canonical and partially complementary binding 
properties of miRNA, nearly half of the miRNA targets 
contain binding sites for at least 2 miRNAs. Therefore, 
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miRNAs binding to the same target can synergise and/or 
antagonise the expression of target genes, making stud-
ies on single miRNAs questionable. 
As discussed by Han et al. [26], statistical signifi-
cance does not necessarily predict the actual clinical 
applicability of molecular markers. The authors found 
that 3 miRNAs were able to predict LNM in a multivari-
ate model. However, there was significant overlap in 
their expression in LNM-positive and LNM-negative 
groups. Only in a minority of cases were miRNA ex-
pression levels high enough to enable segregation of 
LNM-positive cases, providing poor sensitivity at ac-
ceptable levels of specificity.
Conclusions
This research supports the statement that specific up- 
and downregulated miRNAs are associated with LNM 
in PTC patients. However, the prognostic value of these 
miRNAs is limited in individual cases because the distri-
bution of miRNA expression overlaps between patients 
with LNM and without LNM. Analysis of miRNA 
expression levels and detection of circulating or FNA 
miRNAs can be used for the pre-operative diagnosis 
of thyroid cancer cervical lymph node metastasis. To 
translate these data into clinical application, large co-
hort studies are required to examine the prognostic 
and diagnostic value of miRNAs panels. Improved 
standardisation of methods used to assay miRNAs will 
allow more extensive use of this approach in defining 
individualised treatment strategies for thyroid cancer 
patients.
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